Halozyme Therapeutics Presents Positive Pre-Clinical Single Agent Data for PEGPH20
January 26, 2009 08:00 ET
|
Halozyme Therapeutics
Significant Single Agent Anti-Tumor Activity Observed With
PEGPH20 in Tumor Models That Accumulate Hyaluronan
Extended Half-Life of PEGPH20 Allows Continued Depletion of
...
Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial With Second Biologic
January 15, 2009 08:00 ET
|
Halozyme Therapeutics
First Patient Dosed With Second Roche Biologic Formulated With
Halozyme's Recombinant Enzyme Technology
Halozyme to Receive Milestone Payment
SAN DIEGO, Jan....
Halozyme to Present At J.P. Morgan Healthcare Conference
January 08, 2009 08:00 ET
|
Halozyme Therapeutics
SAN DIEGO, Jan. 8, 2009 (GLOBE NEWSWIRE) -- Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the...